Last reviewed · How we verify
NCT03348449: BIRDi
Bitherapy With the Combination of Raltegravir and Darunavir (BIRDi)
trial testing Collection of data in Comorbidities in 360 participants. Completed in 29 June 2018.
15 June 2018
Quick facts
| Lead sponsor | Asociacion para el Estudio de las Enfermedades Infecciosas |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 360 |
| Start date | 15 December 2017 |
| Primary completion | 15 June 2018 |
| Estimated completion | 29 June 2018 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Collection of data
Conditions studied
- Comorbidities — all drugs for Comorbidities →
- HIV/AIDS — all drugs for HIV/AIDS →
Sponsor
Asociacion para el Estudio de las Enfermedades Infecciosas
Who can join
18 and older, any sex, with Comorbidities or HIV/AIDS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Retrospective cohort of virologically suppressed HIV-infected patients who received the combination of Raltegravir plus Darunavir boosted with cobicistat or ritonavir, as dual therapy, because or toxicity or intolerance to nucleoside analogues
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
HIV Glasgow 2018, 28-31 October 2018, Glasgow, UK.
· 2018 · cited 7× · PMID 30362663 · DOI 10.1002/jia2.25187
Verify or expand the search:
- PubMed search for NCT03348449
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Collection of data
Trials testing the same drug.
- NCT05742321 — Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France · recruiting
- NCT04301596 — Assessment of Nutritional Status in Systemic Sclerosis · unknown
- NCT03237299 — Loco-regional Complications of Pharyngitis in Children: a National Case-Control Study · completed
Other recruiting trials for Comorbidities
Currently open trials in the same condition.
- NCT07245680 — COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities · Phase 3 · recruiting
- NCT06759805 — Electronic Cardiac Rehabilitation (eCardiacRehab) Feasibility Study · NA · recruiting
- NCT07165236 — Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor · recruiting
- NCT07289555 — Tailored Stapled SADI-S: Initial Report and Preliminary Results · NA · recruiting
- NCT07269561 — Headache Registration and Followup Initiated by Tongji Hospital, HUST · recruiting
Other Asociacion para el Estudio de las Enfermedades Infecciosas trials
Trials by the same sponsor.
- NCT04526977 — Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis). · unknown
- NCT04402827 — Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19. · completed
- NCT04403061 — Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03348449 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asociacion para el Estudio de las Enfermedades Infecciosas
- Last refreshed: 2 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03348449.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing